| scholarly article | Q13442814 |
| P2093 | author name string | Thomas J Gould | |
| Vinay Parikh | |||
| Munir Gunes Kutlu | |||
| P2860 | cites work | A systematic review of the prevalence of schizophrenia | Q21144720 |
| A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia | Q21203917 | ||
| The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 | ||
| A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors | Q22251463 | ||
| Delay discounting and probability discounting as related to cigarette smoking status in adults | Q23910472 | ||
| Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking | Q24307995 | ||
| Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia | Q24338876 | ||
| Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders | Q24532028 | ||
| GABAergic interneuron origin of schizophrenia pathophysiology. | Q24597790 | ||
| Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons | Q24601769 | ||
| Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition | Q24614080 | ||
| Nicotine dependence and illness severity in schizophrenia | Q44390064 | ||
| Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia | Q44397639 | ||
| A polymorphism in the alpha4 nicotinic receptor gene (Chrna4) modulates enhancement of nicotinic receptor function by ethanol | Q44453582 | ||
| Sensorimotor gating and spatial learning in α7-nicotinic receptor knockout mice | Q44459235 | ||
| Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia | Q44580919 | ||
| Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. | Q44599683 | ||
| Correlations between orbitofrontal dysfunction and tobacco smoking | Q44631573 | ||
| Nicotine improves delayed recognition in schizophrenic patients | Q44784226 | ||
| Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients | Q44853711 | ||
| The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice | Q44916561 | ||
| Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. | Q44919590 | ||
| Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release | Q45200225 | ||
| Synergistic interactions of dopamine D1 and glutamate NMDA receptors in rat hippocampus and prefrontal cortex: involvement of ERK1/2 signaling. | Q45914353 | ||
| Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches | Q24629686 | ||
| A Nicotine Challenge to the Self-Medication Hypothesis in a Neurodevelopmental Animal Model of Schizophrenia | Q24634186 | ||
| GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia | Q24642711 | ||
| Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration | Q24650892 | ||
| Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. | Q27863674 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q28131636 | ||
| A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder | Q28139660 | ||
| Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7) | Q28203593 | ||
| Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia | Q28211739 | ||
| Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies | Q28215775 | ||
| Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study | Q28243031 | ||
| Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors | Q28245329 | ||
| Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation | Q28250054 | ||
| Tropisetron improves deficits in auditory P50 suppression in schizophrenia | Q28253819 | ||
| Nicotine use in schizophrenia: the self medication hypotheses | Q28257325 | ||
| Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia | Q28274346 | ||
| A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia | Q28287576 | ||
| A neurobiological basis for substance abuse comorbidity in schizophrenia | Q28347063 | ||
| Deficits in inhibitory control in smokers during a Go/NoGo task: an investigation using event-related brain potentials | Q28477870 | ||
| Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task | Q28505172 | ||
| Functional characterization of mouse alpha4beta2 nicotinic acetylcholine receptors stably expressed in HEK293T cells | Q28510543 | ||
| The mouse Chrna4 A529T polymorphism alters the ratio of high to low affinity alpha 4 beta 2 nAChRs | Q28513760 | ||
| Alpha7 nicotinic acetylcholine receptors occur at postsynaptic densities of AMPA receptor-positive and -negative excitatory synapses in rat sensory cortex | Q28569404 | ||
| Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways | Q28579410 | ||
| Point mutant mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety. | Q28587412 | ||
| Performance deficit of alpha7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory | Q28588757 | ||
| A polymorphism in the mouse neuronal alpha4 nicotinic receptor subunit results in an alteration in receptor function | Q28589293 | ||
| Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine | Q28589593 | ||
| Executive and social behaviors under nicotinic receptor regulation | Q28591352 | ||
| Cortical inhibitory neurons and schizophrenia | Q29547683 | ||
| Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders | Q30372351 | ||
| Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia | Q30428422 | ||
| The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue | Q30437188 | ||
| Early sensory processing deficits predict sensitivity to distraction in schizophrenia | Q30437690 | ||
| Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis | Q35044540 | ||
| Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits | Q35048154 | ||
| Structurally similar allosteric modulators of α7 nicotinic acetylcholine receptors exhibit five distinct pharmacological effects. | Q35055568 | ||
| Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice | Q35181132 | ||
| Substance abuse in patients with schizophrenia | Q35236689 | ||
| Eye tracking dysfunction in schizophrenia: characterization and pathophysiology | Q35539209 | ||
| Impulsivity and symptoms of nicotine dependence in a young adult population | Q35571767 | ||
| The dopamine D4 receptors and mechanisms of antipsychotic atypicality. | Q35595240 | ||
| The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour | Q35621339 | ||
| Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium | Q35632474 | ||
| Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity | Q35644555 | ||
| Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial | Q35679935 | ||
| Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity | Q35704853 | ||
| Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative trait in two independent samples | Q35752604 | ||
| Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states | Q35802079 | ||
| Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia | Q35837691 | ||
| Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement | Q35844174 | ||
| Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia | Q35880018 | ||
| The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. | Q35957278 | ||
| Association of alpha4beta2 nicotinic receptor and heavy smoking in schizophrenia | Q36141781 | ||
| Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial | Q36149346 | ||
| Schizophrenia and comorbid substance use disorder: effects of antipsychotics | Q36233482 | ||
| Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist | Q36234254 | ||
| Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia | Q36242623 | ||
| Adolescent risk taking, impulsivity, and brain development: implications for prevention | Q36242815 | ||
| Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study | Q36296644 | ||
| Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. | Q36323545 | ||
| Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers | Q36350246 | ||
| Externalizing behaviors are associated with SNPs in the CHRNA5/CHRNA3/CHRNB4 gene cluster | Q36422737 | ||
| α4β2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief | Q36517174 | ||
| Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia | Q36579938 | ||
| Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates | Q36582006 | ||
| Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system | Q36607367 | ||
| It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood | Q36666651 | ||
| Smoking and mental illness: A population-based prevalence study | Q39513259 | ||
| alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability | Q39651145 | ||
| Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. | Q40056642 | ||
| Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains | Q40551081 | ||
| CHRNA7 and CHRFAM7A mRNAs: co-localized and their expression levels altered in the postmortem dorsolateral prefrontal cortex in major psychiatric disorders | Q40702035 | ||
| Why some people smoke and others do not: new perspectives | Q40782265 | ||
| Symptom correlates of prepulse inhibition deficits in male schizophrenic patients | Q40817813 | ||
| Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. | Q40821290 | ||
| Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain | Q40926398 | ||
| The prodromal phase of first-episode psychosis: past and current conceptualizations | Q41091264 | ||
| Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or alpha 4 beta 2 receptors to nicotine | Q41257870 | ||
| Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia | Q41667137 | ||
| Parvalbumin-containing interneurons of the human cerebral cortex express nicotinic acetylcholine receptor proteins | Q42505129 | ||
| Second-by-second analysis of alpha 7 nicotine receptor regulation of glutamate release in the prefrontal cortex of awake rats | Q42580171 | ||
| Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors | Q42671767 | ||
| In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease | Q43053668 | ||
| Hyperactive mice show elevated D2(High) receptors, a model for schizophrenia: Calcium/calmodulin-dependent kinase II alpha knockouts | Q43119211 | ||
| Nicotine provokes impulsive-like action by stimulating alpha4beta2 nicotinic acetylcholine receptors in the infralimbic, but not in the prelimbic cortex | Q43125451 | ||
| Substance use disorders in schizophrenia--clinical implications of comorbidity | Q43145195 | ||
| ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects | Q43197577 | ||
| Varenicline modulates spatial working memory deficits in smokers with schizophrenia | Q43547568 | ||
| Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice | Q43766045 | ||
| Effects of smoking abstinence on visuospatial working memory function in schizophrenia | Q43829054 | ||
| Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas | Q43925474 | ||
| Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory | Q43942893 | ||
| Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia | Q44133505 | ||
| The effects of nicotine on specific eye tracking measures in schizophrenia | Q44174116 | ||
| Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study | Q44237583 | ||
| Tobacco use before, at, and after first-episode psychosis: a systematic meta-analysis | Q44275064 | ||
| Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex | Q44317337 | ||
| Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats | Q44317363 | ||
| The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy. | Q34419501 | ||
| Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity | Q34455264 | ||
| Role of anticipation in schizophrenia-related pursuit initiation deficits | Q34464832 | ||
| Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia | Q34481351 | ||
| ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study | Q34497533 | ||
| Cellular mechanisms of nicotine addiction | Q34498016 | ||
| Hippocampal changes produced by overexpression of the human CHRNA5/A3/B4 gene cluster may underlie cognitive deficits rescued by nicotine in transgenic mice | Q34537418 | ||
| From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment | Q34632695 | ||
| Brain states: top-down influences in sensory processing | Q34635087 | ||
| Nicotinic acetylcholine receptors as targets for antidepressants. | Q34761238 | ||
| Initial phase 2 trial of a nicotinic agonist in schizophrenia | Q34766663 | ||
| Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties | Q34778803 | ||
| Reward processing in schizophrenia: a deficit in the representation of value | Q34790612 | ||
| Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome | Q34868588 | ||
| Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. | Q34926526 | ||
| alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex | Q34935099 | ||
| Structural and functional diversity of native brain neuronal nicotinic receptors | Q34983875 | ||
| Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596. | Q34997975 | ||
| Gene-gene interactions among CHRNA4, CHRNB2, BDNF, and NTRK2 in nicotine dependence | Q30437713 | ||
| Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice | Q30443234 | ||
| Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor | Q30453198 | ||
| TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia | Q30478035 | ||
| Prepulse inhibition and genetic mouse models of schizophrenia | Q30478270 | ||
| P50 sensory gating is related to performance on select tasks of cognitive inhibition | Q30483872 | ||
| Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research | Q30485478 | ||
| Cognitive functioning in the schizophrenia prodrome | Q30491319 | ||
| Smoking, Genetics and Schizophrenia: Evidence for Self Medication | Q30491841 | ||
| Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. | Q30493072 | ||
| Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats | Q30501701 | ||
| Does tobacco use cause psychosis? Systematic review and meta-analysis | Q30694281 | ||
| beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking | Q33551855 | ||
| Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers | Q33598688 | ||
| In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia | Q33605318 | ||
| A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia | Q33620592 | ||
| P50, N100, and P200 sensory gating: relationships with behavioral inhibition, attention, and working memory | Q33651455 | ||
| Cross-species studies of sensorimotor gating of the startle reflex | Q33692772 | ||
| Is initiation of smoking associated with the prodromal phase of schizophrenia? | Q33708525 | ||
| Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia | Q33725848 | ||
| Impulsivity: a discussion of clinical and experimental findings | Q33727737 | ||
| Clinical characteristics of heavy and non-heavy smokers with schizophrenia | Q33775576 | ||
| Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling | Q33830056 | ||
| Effect of second-generation antipsychotics on cognition: current issues and future challenges | Q33888153 | ||
| AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. | Q33899354 | ||
| Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia | Q33920507 | ||
| Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. | Q34014716 | ||
| Chrna4 A529 knock-in mice exhibit altered nicotine sensitivity | Q34058860 | ||
| Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. | Q34268442 | ||
| Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction | Q34317550 | ||
| Is schizophrenia a dopamine supersensitivity psychotic reaction? | Q34377871 | ||
| Hippocampal neurons in schizophrenia | Q34383604 | ||
| Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia | Q34397600 | ||
| Presynaptic nicotinic ACh receptors | Q34415708 | ||
| Patterns of premorbid functioning in first-episode psychosis: initial presentation | Q60998116 | ||
| Smoking as a causal risk factor for schizophrenia | Q61822104 | ||
| Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome | Q64780587 | ||
| Smoking and schizophrenia | Q67524559 | ||
| Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo | Q71673032 | ||
| Nicotinic receptors, smoking and schizophrenia | Q73205997 | ||
| Smoking and schizophrenia: abnormal nicotinic receptor expression | Q73689160 | ||
| Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies | Q73818355 | ||
| Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients | Q74204098 | ||
| Associations of P50 suppression and desensitization with perceptual and cognitive features of "unreality" in schizotypy | Q74535938 | ||
| Smoking and therapeutic response to clozapine in patients with schizophrenia | Q77963317 | ||
| The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls | Q80178742 | ||
| Prevalence of atherosclerotic plaque in young and middle-aged asymptomatic individuals: the Bogalusa heart study | Q82533773 | ||
| Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice | Q83227949 | ||
| CNS localization of neuronal nicotinic receptors. | Q36694063 | ||
| Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium | Q36695036 | ||
| Schizophrenia from a neuropsychiatric perspective. | Q36695324 | ||
| A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia | Q36775219 | ||
| How should DSM-V criteria for schizophrenia include cognitive impairment? | Q36849096 | ||
| Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine | Q36883052 | ||
| Psychiatric considerations in pulmonary disease | Q36972193 | ||
| Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions | Q37000906 | ||
| Systematic biological prioritization after a genome-wide association study: an application to nicotine dependence | Q37029791 | ||
| Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice | Q37089670 | ||
| Impulsiveness and cigarette smoking | Q37267747 | ||
| Smooth pursuit in schizophrenia: a meta-analytic review of research since 1993. | Q37290647 | ||
| Does delay discounting play an etiological role in smoking or is it a consequence of smoking? | Q37345565 | ||
| Nicotinic receptors containing the alpha7 subunit: a model for rational drug design | Q37347201 | ||
| Baseline impulsive choice predicts the effects of nicotine and nicotine withdrawal on impulsivity in rats. | Q37381476 | ||
| Sensory processing in schizophrenia: neither simple nor intact | Q37388966 | ||
| Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia | Q37436125 | ||
| Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction | Q37525085 | ||
| Effects of smoking abstinence on cigarette craving, nicotine withdrawal, and nicotine reinforcement in smokers with and without schizophrenia | Q37576343 | ||
| Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia | Q37631610 | ||
| Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status | Q37693834 | ||
| The therapeutic promise of positive allosteric modulation of nicotinic receptors | Q37695734 | ||
| Nicotine addiction and nicotinic receptors: lessons from genetically modified mice | Q37756527 | ||
| Presynaptic nicotinic receptors modulating neurotransmitter release in the central nervous system: functional interactions with other coexisting receptors. | Q37766017 | ||
| A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia | Q37962995 | ||
| Impulsive behavior and nicotinic acetylcholine receptors | Q37996915 | ||
| Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans | Q38035216 | ||
| Nicotinic receptors in addiction pathways | Q38068126 | ||
| Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems | Q38122913 | ||
| Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings | Q38124448 | ||
| α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia | Q38151181 | ||
| A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder | Q38469664 | ||
| The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia | Q38560778 | ||
| Nicotine Addiction and Psychiatric Disorders | Q38608639 | ||
| Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls | Q39372058 | ||
| A physiological role for GABAB receptors in the central nervous system. | Q46128796 | ||
| Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats | Q46182609 | ||
| Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia | Q46230735 | ||
| P50 gating at acute and post-acute phases of first-episode schizophrenia | Q46311180 | ||
| Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats | Q46490757 | ||
| Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms | Q46531414 | ||
| Effect of fluoxetine on neuromuscular function in acetylcholinesterase (AChE) knockout mice | Q46543389 | ||
| Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex | Q46667136 | ||
| Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central alpha7 nicotinic acetylcholine receptors | Q46745299 | ||
| Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia | Q46794316 | ||
| Galantamine for the treatment of cognitive impairments in people with schizophrenia | Q46911906 | ||
| Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats | Q46990157 | ||
| Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. | Q47668148 | ||
| Schizophrenia, sensory gating, and nicotinic receptors | Q48012124 | ||
| Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. | Q48104071 | ||
| Nicotinic acetylcholine receptor β2 subunits in the medial prefrontal cortex control attention | Q48118545 | ||
| Inhibition control impairments in adolescent smokers: electrophysiological evidence from a Go/NoGo study | Q48119082 | ||
| Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats | Q48170487 | ||
| Frontal cortical alpha7 and alpha4beta2 nicotinic acetylcholine receptors in working and reference memory | Q48177575 | ||
| The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents | Q48269550 | ||
| Neurophysiologic studies of sensory gating in schizophrenia: comparison of auditory and visual responses | Q48430923 | ||
| Cholinergic gating of response to auditory stimuli in rat hippocampus | Q48453728 | ||
| Prepulse inhibition and P50 suppression: commonalities and dissociations | Q48458227 | ||
| Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed, and nonpatient smokers | Q48606772 | ||
| Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. | Q48739569 | ||
| PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. | Q48767121 | ||
| Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine | Q48915839 | ||
| Quantitative characterization of eye tracking dysfunction in schizophrenia | Q49063458 | ||
| Pursuit tracking impairments in schizophrenia and mood disorders: step-ramp studies with unmedicated patients | Q49075830 | ||
| Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. | Q50642227 | ||
| Trait differences in response to chronic nicotine and nicotine withdrawal in rats. | Q50721887 | ||
| Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. | Q50750333 | ||
| AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. | Q50891788 | ||
| The effect of auditory and visual stimulation on the skin potential response of schizophrenics. | Q51310209 | ||
| Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients. | Q51616422 | ||
| Datapoints: Smoking and smoking cessation among persons with severe mental illnesses. | Q51919254 | ||
| Prepulse inhibition deficits in schizophrenia are modified by smoking status. | Q51935219 | ||
| Sensory gating revisited: relation between brain oscillations and auditory evoked potentials in schizophrenia. | Q51968676 | ||
| Galantamine improves cognition in schizophrenic patients stabilized on risperidone. | Q51981422 | ||
| Familial transmission of two independent saccadic abnormalities in schizophrenia. | Q52038631 | ||
| Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. | Q52144163 | ||
| Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers. | Q52173361 | ||
| Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. | Q52299798 | ||
| Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. | Q52563684 | ||
| Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. | Q52582625 | ||
| Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement. | Q52717708 | ||
| Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. | Q54504238 | ||
| Preclinical Characterization of A-582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties | Q56853416 | ||
| Further investigation of a chromosome 15 locus in schizophrenia: Analysis of affected sibpairs from the NIMH genetics initiative | Q57400539 | ||
| Measures of impulsivity in cigarette smokers and non-smokers | Q60611842 | ||
| P433 | issue | 1-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| nicotine | Q12144 | ||
| comorbidity | Q1414874 | ||
| P304 | page(s) | 1-15 | |
| P577 | publication date | 2016-01-20 | |
| P1433 | published in | Schizophrenia Research | Q7431607 |
| P1476 | title | nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. | |
| P478 | volume | 171 |
| Q49870570 | Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach |
| Q58712660 | C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review |
| Q47558509 | CHRFAM7A gene expression in schizophrenia: clinical correlates and the effect of antipsychotic treatment. |
| Q47760005 | Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort. |
| Q38820699 | Effects of drugs of abuse on hippocampal plasticity and hippocampus-dependent learning and memory: contributions to development and maintenance of addiction |
| Q37411892 | High-Affinity α-Conotoxin PnIA Analogs Designed on the Basis of the Protein Surface Topography Method. |
| Q46311520 | Human brain imaging of nicotinic acetylcholine α4β2* receptors using [18 F]Nifene: Selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways. |
| Q58795483 | Mechanisms Underlying the Strong Inhibition of Muscle-Type Nicotinic Receptors by Tetracaine |
| Q50174023 | Motives and perceptions regarding electronic nicotine delivery systems (ENDS) use among adults with mental health conditions. |
| Q57478268 | Multi-Target Approach for Drug Discovery against Schizophrenia |
| Q60046151 | Neurobiological Determinants of Tobacco Smoking in Schizophrenia |
| Q91705551 | Nicotine consumption during the prodromal phase of schizophrenia - a review of the literature |
| Q47921866 | Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset |
| Q50113143 | Precisely Timed Nicotinic Activation Drives SST Inhibition in Neocortical Circuits |
| Q91638660 | Prevalence and smokers' profile: comparisons between the psychiatric population and the general population |
| Q47135096 | Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments |
| Q33920223 | Repeated Nicotine Strengthens Gamma Oscillations in the Prefrontal Cortex and Improves Visual Attention |
| Q38972963 | The challenge of reducing smoking in people with serious mental illness |
| Q96219325 | Tobacco smoking, related harm and motivation to quit smoking in people with schizophrenia spectrum disorders |
| Q37628685 | Use of Electronic Nicotine Delivery Systems among Adults with Mental Health Conditions, 2015 |
| Q90666112 | Use of tobacco in schizophrenia: A double-edged sword |
| Q37456022 | Views and Preferences for Nicotine Products as an Alternative to Smoking: A Focus Group Study of People Living with Mental Disorders |
| Q47211543 | α5 nAChR modulation of the prefrontal cortex makes attention resilient |
| Q89428242 | α5 nicotinic receptors link smoking to schizophrenia |
| Q52562792 | α7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia. |
Search more.